ID: MRFR/HC/6975-HCR | February 2021 | Region: Global | 90 pages
Antibiotics Market is expected to cross USD 64,532 Million by 2025 at a CAGR of 4.8%.
Supportive government legislations, such as the implementation of the Generating Antibiotics Incentives Now (GAIN) Act in the US, are expected to accelerate the drug approval process in the antibiotics market.
GAIN Act facilitates the development of therapies against antibiotic-resistant pathogens. Thus, by this act, there is a rise in antibiotic approval in the US, with an average yearly approval rate more than double from 2000-2012 (0.8 approvals per year) to 2013-present (1.8 approvals per year). This creates a lucrative opportunity for the companies to enter the antibiotics market, thus fueling the market growth.
An increasing number of antibiotics in the clinical development stage. In June 2019, approximately 42 new antibiotics with the ability to treat severe bacterial infections were in the clinical development stage. As a result, increasing the number of antibiotics would drive the demand for the antibiotics market.
Major companies undertook increasing efforts for the development of advanced antibiotics. According to the data published by the Pew Charitable Trust, in March 2016, clinical research was conducted for approximately 37 drug molecules within the US market. Majority of these molecules are in phase II clinical trials and are anticipated to launch in the near future, thus accelerating the growth of antibiotics market
Increasing approval of antibiotic drugs. In 2018, about 59 antibiotic drugs such as xospata, firdapse, and asparlas were approved by the US Food and Drug Administration (FDA).
The rise in the incidence of chronic and infectious diseases. There has been an increase in infectious disease rates. For instance, more than 17 million people were affected by contagious diseases globally.
Growing investment opportunities by biotech companies in research & development. As of June 2019, approximately 42 new antibiotics with the potential to treat severe bacterial infections are in clinical development
Development of generic drugs
By Drug class
Cephalosporins: They are class of β-lactam antibiotics originally derived from Acremonium and are effective against a wide range of bacteria. They kill bacteria and have similar functions to that of penicillin.
Penicillin: Penicillin is used to treat bacterial infections. It is primarily used for the treatment of various diseases such as pneumonia, meningitis, endocarditis, and others.
Fluoroquinolones: Fluoroquinolones are used to treat respiratory and urinary tract infections (UTIs).
Macrolides: Macrolide antibiotics are effective in treating bacterial infections such as ear, nose, and throat infections, chest infections, skin infections, and mouth and dental infections.
Carbapenem: Fastest-growing segment. Growing incidence of UTIs pneumonia and bloodstream infections are expected to increase the usage of carbapenems class of antibiotics. In 2016, the consumption of carbapenems in Europe was approximately 0.05 defined daily doses (DDD) per 1,000 people per day.
Aminoglycosides: Aminoglycosides are a class of antibiotics that are used mainly in the treatment of aerobic gram-negative bacilli infections.
Sulfonamides: Contains sulfonamide chemical group. This class of antibiotics is used in diabetes and pain relief.
Others: Others include tetracyclines, monoclonal antibodies, imidazoles, and lincosamides.
By Spectrum of Activity
Broad-spectrum Antibiotic: Largest segment. Broad-Spectrum antibiotics act against a wide range of diseases, which in turn helps to fight against antimicrobial resistance, thus driving the growth of this segment. Examples include aminoglycosides, cephalosporins, and quinolones.
Narrow-spectrum Antibiotic: Narrow-spectrum antibiotics are active against selected types of bacteria. Examples include macrolides and vancomycin.
By Drug Origin
Natural: Derived from natural sources such as plant extracts and essential oils that have antibiotic properties.
Semi-synthetic: Fastest-growing segment. Semi-synthetic antibiotics are the derivatives of natural antibiotics with somewhat different but useful characteristics. They can act against bacteria that are resistant to the original compound, have a broad-spectrum of activity, and cause fewer side-effects. An example of semisynthetic includes ampicillin drug.
Synthetic: Related to natural antibiotics. It includes the quinolone class of antibiotics.
Hospitals & Clinics: The largest segment, a majority of treatment and procedures are carried out in hospitals. In 2016, the average consumption of antibiotics for systemic use in hospitals was 2.1 defined daily doses (DDD) per 1,000 people per day.
Research Organizations: They encourage the research & development of new antimicrobial drugs and diagnostics, thus would drive the growth of the antibiotics market. Global Antibiotic Research & Development Partnership address global public health needs by delivering and developing new or improved antibiotic treatments.
Others: Others include academic institutes, nursing homes, and emergency care centers.
Americas: The largest regional market. Rising growth in the pharmaceutical sector, increasing adoption of antibiotics, are the significant factors that would drive the growth of the antibiotics market in this region.
Europe: Rising consumption of antibiotics, high prevalence of infectious diseases, increase in usage of generic medicines. These factors are anticipated to drive the growth of the antibiotics market in this region.
Asia-Pacific: The fastest-growing regional market in antibiotics owing to the rising consumption of antibiotics, an increase in the sale of over the counter (OTC) drugs, and the easy availability of drugs.
Middle East & Africa: Increasing healthcare expenditure and rising consumption of antibiotics would drive the demand for the antibiotics market in this region.
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug class, Spectrum of Activity, Drug Origin, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Abbott Laboratories (US), GlaxoSmithKline PLC (UK), Sanofi (France), Novartis AG (Switzerland),Bayer AG (Germany), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Antibiotics are powerful medicines that fight bacterial infections. They either stop bacteria from reproducing or destroy them. Several types of antibiotics are available, and they are generally available with a prescription in most countries.
Types of Antibiotics - Cephalosporins, Penicillin, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, Others
The valuation of the antibiotics market is estimated to reach USD 64,532 MN by 2025.
The antibiotics market is projected to grow at approximately 4.8% CAGR during the forecast period (2019-2025).
Increasing investment by major companies in antibiotics research & development (R&D).
North America holds the largest share in the global antibiotics market, followed by Europe and the Asia Pacific, respectively.
Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Abbott Laboratories (US), Sanofi (France), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Astellas Pharma Inc. (Japan), Eli Lilly and Company (US), Merck & Co., Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland), are some of the major players operating in the antibiotics market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.